Delisting risk
VSee Health (VSEE)
Remote acute-care physician services and clinical technology for institutional settings.
$0.0169
At close+0.00 (+5.63%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 1 | 1 | 2 | 3 | 4 | 3 | 3 | 4 | 4 | 3 | 2 |
| Cost of revenue | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| Gross profit | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 0 |
| 1 | 1 | 1 | 2 | 59 | 6 | 4 | 4 | 4 | 5 | 3 | 2 | |
| 1 | 1 | 1 | 1 | 4 | 6 | 3 | 3 | 4 | 5 | 3 | 2 | |
| Selling & marketing | 0 | 1 | 1 | 1 | 2 | 2 | 0 | 2 | 1 | 2 | 0 | 0 |
| General & administrative | 0 | 0 | 0 | 1 | 2 | 4 | 3 | 2 | 3 | 3 | 3 | 2 |
| Other expenses | 1 | 0 | 0 | 1 | 56 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Operating income | 0 | 0 | 0 | −1 | −57 | −4 | −2 | −2 | −2 | −3 | −2 | −3 |
| 0 | 0 | 0 | −1 | 5 | −1 | −2 | 0 | 2 | −4 | −1 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | −1 | −56 | −1 | 1 | 0 | −3 | 3 | 1 | 0 |
| Income before tax | 0 | 0 | 0 | −3 | −52 | −4 | −4 | −3 | 0 | −8 | −3 | −3 |
| Income tax expense | 0 | 2 | 0 | −2 | −1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | 0 | −3 | 0 | 0 | −52 | −6 | −4 | −3 | 0 | −8 | −3 | −3 |
| Net income | 0 | −3 | 0 | 0 | −52 | −6 | −4 | −3 | 0 | −8 | −3 | −3 |
| EPS, basic | −$0.01 | −$0.28 | −$0.00 | −$0.06 | −$3.43 | −$0.36 | −$0.24 | −$0.16 | −$0.02 | −$0.31 | −$0.05 | −$0.06 |
| EPS, diluted | −$0.01 | −$0.28 | −$0.00 | −$0.06 | −$3.43 | −$0.36 | −$0.24 | −$0.16 | −$0.02 | −$0.31 | −$0.05 | −$0.06 |
| Weighted average shares, basic | 10 | 10 | 10 | 5 | 15 | 16 | 16 | 16 | 17 | 20 | 48 | 54 |
| Weighted average shares, diluted | 10 | 10 | 10 | 5 | 15 | 16 | 16 | 16 | 17 | 20 | 48 | 54 |
| EBITDA | 0 | 0 | 0 | 0 | −1 | −2 | −3 | −2 | 1 | −6 | −2 | −2 |
| Depreciation & amortization | 0 | 0 | — | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBIT | 0 | 0 | 0 | 0 | −1 | −3 | −3 | −2 | 0 | −7 | −3 | −3 |